What clinical data shows on lurbinectedin and fertility
Lurbinectedin (brand name Zepzelca), approved for small cell lung cancer, carries warnings about potential fertility impairment in both men and women. Prescribing information states it can cause irreversible infertility due to effects on germ cells, based on animal studies where females showed ovarian atrophy, reduced fertility, and embryo-fetal toxicity at doses below human equivalents.[1] No direct long-term human fertility studies exist, as trials focused on advanced cancer patients not typically seeking pregnancy.
Animal evidence for ovarian damage
In rats and monkeys, lurbinectedin caused dose-dependent ovarian toxicity, including follicular atresia and decreased corpora lutea, persisting post-treatment. These changes suggest permanent effects on ovarian reserve, a key factor in long-term fertility for women.[1]
Recommendations for women of childbearing potential
Women are advised to use effective contraception during treatment and for 6 months after the last dose. Premenopausal patients should discuss fertility preservation (e.g., egg freezing) before starting, as ovarian function may not recover.[1] No routine fertility monitoring is specified post-treatment.
Comparison to similar chemotherapy agents
Like platinum-based drugs (e.g., cisplatin) often paired with lurbinectedin, it risks premature ovarian insufficiency. Studies on alkylating agents show 20-80% infertility rates in survivors, varying by age and cumulative dose—patterns likely applicable here, though specific lurbinectedin data is limited.[2]
Patient experiences and real-world reports
Limited case reports note amenorrhea in female patients post-treatment, but no large-scale fertility outcome studies. Cancer forums and survivorship data highlight concerns for younger women, with some regaining menses but facing early menopause risks.[3]
[1] Zepzelca (lurbinectedin) prescribing information, Jazz Pharmaceuticals, https://www.zepzelca.com/pdf/zepzelca-prescribing-information.pdf
[2] NCCN Guidelines for Ovarian Function Preservation in Cancer, Version 1.2023, https://www.nccn.org/guidelines
[3] ASCO survivorship guidelines on fertility preservation, https://ascopubs.org/doi/full/10.1200/JCO.19.02086